CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 213 enrolled
Drug / intervention
Setmelanotidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03013543
NCT03013543Phase 2Completed
CompareCT.gov

Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity

Rhythm Pharmaceuticals, Inc.·interventional·Posted Jan 6, 2017·Updated Aug 18, 2023

In Brief

A Phase 2 clinical trial evaluating Setmelanotide for Genetic Obesity and 2 related conditions. Completed, enrolled 213 participants across 58 sites in 9 countries.

Detailed Summary

The purpose of the study was to determine the effect of setmelanotide (RM-493) on weight, hunger assessments, and other factors in participants with rare genetic disorders of obesity.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGenetic Obesity, Obesity, Obesity Due to Melanocortin 4 Receptor Deficiency
CountriesCanada, France, Germany, Greece, Israel, Netherlands, Spain, United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 6, 2017
Enrollment StartFeb 10, 2017
Primary CompletionMar 1, 2022
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 9.5 years ago

Interventions

Setmelanotidedrug

RM-493 QD SC injection